Neoadjuvant Chemoradiotherapy (CRT) Archives

Pivotal Phase 3 Data for Keytruda in High-Risk Early-Stage TNBC Published in the New England Journal of Medicine

Blockbusters, Chemotherapy, Clinical Trials, Event-Free Survival (EFS), Keytruda, Neoadjuvant Chemoradiotherapy (CRT), New England Journal of Medicine, New Indications, R&D, Triple Negative Breast Cancer (TNBC)

Merck announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant Keytruda in combination with chemotherapy followed by adjuvant Keytruda as monotherapy, significantly prolonged event-free survival compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer (TNBC).

February 9, 2022/by Business Wire

U.S. FDA Approves Opdivo for Adjuvant Treatment of Certain GI Patients

Approvals, Blockbusters, Bristol Myers Squibb, Clinical Trials, Esophageal Cancer, FDA, Gastroesophageal Junction (GEJ) Adenocarcinoma, Immunotherapies, Neoadjuvant Chemoradiotherapy (CRT), New Indications, R&D, Therapeutics

The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).

May 20, 2021/by Andrew Humphreys